147 related articles for article (PubMed ID: 11068938)
1. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease.
Colao A; Pivonello R; Lastoria S; Faggiano A; Ferone D; Lombardi G; Fenzi G
Eur J Endocrinol; 2000 Oct; 143 Suppl 1():S35-42. PubMed ID: 11068938
[No Abstract] [Full Text] [Related]
2. Somatostatin-receptor scintigraphy in Graves' orbitopathy.
Postema PT; Kwekkeboom DJ; van Hagen PM; Krenning EP
Eur J Nucl Med; 1996 Jun; 23(6):615-7. PubMed ID: 8662098
[No Abstract] [Full Text] [Related]
3. What is a false-positive somatostatin receptor scintigraphy?
Reubi JC
J Nucl Med; 1998 Dec; 39(12):2193-4. PubMed ID: 9867170
[No Abstract] [Full Text] [Related]
4. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy.
Chen CC; Czerwiec FS; Feuillan PP
J Nucl Med; 1998 Feb; 39(2):238-40. PubMed ID: 9476926
[TBL] [Abstract][Full Text] [Related]
5. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
[TBL] [Abstract][Full Text] [Related]
6. [Isotopic scan with somatostatin receptors in a case of recurrent carcinoid tumor. Relevance of tomographic detection].
Bernà Roqueta L; Martín Marimón JC; Martín Martínez J
Rev Esp Med Nucl; 2002 Apr; 21(2):123-4. PubMed ID: 11879622
[No Abstract] [Full Text] [Related]
7. Somatostatin receptors and breast cancer.
van Eijck CH; Kwekkeboom DJ; Krenning EP
Q J Nucl Med; 1998 Mar; 42(1):18-25. PubMed ID: 9646641
[TBL] [Abstract][Full Text] [Related]
8. Indium 111 octreotide scintigraphy in angiofibroma.
Guneri EA; Degirmenci B; Durak H; Ikiz AO; Derebek E; Sutay S
Otolaryngol Head Neck Surg; 1998 Jan; 118(1):137-9. PubMed ID: 9450844
[No Abstract] [Full Text] [Related]
9. An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: usefulness of hepatobiliary imaging for differential diagnosis.
Kurtaran A; Ofluoglu S; Traub T; Tribl B; Speiser P; Grabenwöger F; Schima W; Dudczak R; Virgolini I
Am J Gastroenterol; 2000 May; 95(5):1367-8. PubMed ID: 10811361
[No Abstract] [Full Text] [Related]
10. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
11. Incidental appendix carcinoid. Value of somatostatin receptor imaging.
Hoegerle S; Nitzsche EU; Stumpf A; Simon GH; Otte A; Schwarzkopf G; Moser E
Clin Nucl Med; 1997 Jul; 22(7):467-9. PubMed ID: 9227869
[TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis in a clinically unaffected joint demonstrated by somatostatin receptor scintigraphy.
Kroot EJ; Dolhain RJ; van Hagen PM; Kwekkeboom DJ
Clin Nucl Med; 2006 Aug; 31(8):501-3. PubMed ID: 16855445
[No Abstract] [Full Text] [Related]
13. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
[TBL] [Abstract][Full Text] [Related]
14. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
[TBL] [Abstract][Full Text] [Related]
15. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
16. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor imaging: current status and future perspectives.
Bohuslavizki KH
J Nucl Med; 2001 Jul; 42(7):1057-8. PubMed ID: 11438628
[No Abstract] [Full Text] [Related]
18. Somatostatin receptor-based imaging in malignant lymphomas.
O'Brien JP
J Nucl Med; 1995 Jan; 36(1):19-20. PubMed ID: 7799074
[No Abstract] [Full Text] [Related]
19. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
20. Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in graves' disease.
Gabriel M; Decristoforo C; Moncayo R
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1267. PubMed ID: 12418470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
